Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilpivirine - Janssen R&D Ireland

Drug Profile

Rilpivirine - Janssen R&D Ireland

Alternative Names: Edurant; G002 - Janssen Therapeutics; G007; G009-01; JNJ-16150108; Long-acting TMC278; R 278474; Rekambys; Rilpivirine hydrochloride; TMC 278; TMC-278-A; TMC278 LA (IM injection) - Tibotec; TMC278LA

Latest Information Update: 16 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland; Janssen Therapeutics; National Institute of Allergy and Infectious Diseases; PATH; ViiV Healthcare
  • Class Antiretrovirals; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 16 Nov 2021 Phase-I clinical trials in HIV-1 infections (In volunteers) in Netherlands and USA (SC) (NCT05112939)
  • 09 Nov 2021 Phase-I/II clinical trials in HIV-1 infections (In children, In adolescents, Treatment-experienced) in South Africa, Thailand (PO) (NCT03497676)
  • 03 Nov 2021 Janssen Research & Development plans a phase I trial in Healthy volunteers in USA and Netherlands (SC, Suspension) (NCT05112939)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top